Physician profile
Daniela Jodorkovsky
NPI 1891932455
$2,397.54
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $360 · 2020: $231 · 2021: $915 · 2022: $362 · 2023: $201 · 2024: $328.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $529.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $529.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $781.96 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $281.90 | 2019-2021 | |
| Abbvie INC. | $270.75 | 2021-2022 | |
| Enterra Medical, INC. | $182.59 | 2024 | |
| Medtronic, INC. | $160.83 | 2023 | Interstim |
| Nestle Healthcare Nutrition INC. | $157.53 | 2020-2022 | |
| Laborie Medical Technologies Corp. | $145.80 | 2024 | Alphaone |
| Redhill Biopharma INC. | $111.65 | 2021 | |
| Allergan, INC. | $73.22 | 2019-2020 | |
| Shire North American Group INC | $71.19 | 2019 | |
| Genzyme Corporation | $39.92 | 2023 | |
| Evoke Pharma, INC. | $28.94 | 2021 | |
| Ucb, INC. | $26.74 | 2019 | |
| Ardelyx, INC. | $20.41 | 2022 | |
| Merck Sharp & Dohme LLC | $17.00 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $15.08 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $12.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniela Jodorkovsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.